REZOLVE-AD study met all primary and key secondary endpoints, including

REZOLVE-AD 研究达到了所有主要终点和关键次要终点，包括

EASI-75,

EASI-75，

EASI-90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w

使用雷泽佩加德斯白介素-2（rezpegaldesleukin）24 µg/kg，每两周一次给药后的EASI-90、瘙痒数值评定量表（NRS）、研究者总体评估特应性皮炎（vIGA-AD）和体表面积（BSA）

First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease

首个支持Treg调节作为慢性炎症性疾病免疫调控临床机制的大规模安慰剂对照试验

Findings support the continued development of rezpegaldesleukin in the ongoing Phase 3 ZENITH AD clinical program

研究结果支持在正在进行的III期ZENITH AD临床项目中继续开发rezpegaldesleukin

SAN FRANCISCO

旧金山

,

，

Aug. 25, 2026

2026年8月25日

/PRNewswire/ -- Nektar Therapeutics (Nasdaq:

/美通社/ -- Nektar Therapeutics（纳斯达克：

NKTR

NKTR

) today announced the publication of peer-reviewed data from the 16-week induction period of REZOLVE-AD, a global, randomized, double-blind, placebo-controlled Phase 2b study evaluating rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis (AD). The publication in

）今日宣布发表来自REZOLVE-AD研究16周诱导期的同行评审数据。REZOLVE-AD是一项全球性、随机、双盲、安慰剂对照的2b期临床试验，旨在评估rezpegaldesleukin在治疗中重度特应性皮炎（AD）成人患者中的疗效。该研究成果发表于

The Lancet

《柳叶刀》

, a world-leading medical journal, provides the medical and scientific community with the full reporting of efficacy, safety, pharmacodynamics, pharmacokinetics, and biomarker findings from the 16-week induction period of the Phase 2b trial.

《柳叶刀》作为全球领先的医学期刊，向医学和科学界全面报道了2b期临床试验16周诱导期的疗效、安全性、药效学、药代动力学及生物标志物研究结果。

Rezpegaldesleukin is a first-in-class regulatory T-cell (T-reg) biologic designed to address imbalances in the immune system that underlie many autoimmune disorders and chronic inflammatory conditions. It targets the IL-2 receptor complex to preferentially stimulate the proliferation of T-regs to restore immune balance..

Rezpegaldesleukin 是一款首创的调节性T细胞（T-reg）生物制剂，旨在纠正许多自身免疫性疾病和慢性炎症性疾病背后的免疫系统失衡。它靶向IL-2受体复合物，优先刺激T-reg细胞的增殖，以恢复免疫平衡。

'These results represent the first large, randomized, placebo-controlled trial to demonstrate that selectively expanding regulatory T cells can translate into clinically meaningful improvements across both physician-assessed and patient-reported outcomes in patients with atopic dermatitis,' said Jonathan I.

“这些结果代表了首个大型、随机、安慰剂对照试验，证明了选择性扩增调节性T细胞可以转化为特应性皮炎患者在医生评估和患者报告结局方面的临床意义改善。”乔纳森·I说。

Silverberg, M.D., Ph.D., M.P.H., Professor of Dermatology at George Washington University School of Medicine and Principal Investigator of the REZOLVE-AD study. 'The rapid onset of efficacy, paired with consistency of responses across disease severity and a good safety profile, highlights the unique promise of rezpegaldesleukin.

Silverberg 医学博士、哲学博士、公共卫生硕士，乔治华盛顿大学医学院皮肤病学教授，REZOLVE-AD 研究的主要研究者。“疗效迅速起效，结合在不同疾病严重程度下反应的一致性，以及良好的安全性特征，凸显了 rezpegaldesleukin 的独特潜力。”

With a T-reg mechanism that works upstream of currently available targeted agents, we have the opportunity with rezpegaldesleukin to alter the treatment paradigm and provide a novel alternative for the many patients with moderate-to-severe atopic dermatitis who are inadequately treated today.'.

凭借一种作用于当前可用靶向药物上游的T调节机制，我们有机会通过rezpegaldesleukin改变治疗模式，为众多目前治疗不足的中重度特应性皮炎患者提供一种全新的替代方案。

The REZOLVE-AD trial was conducted across 107 sites in 10 countries, analyzing 393 biologic- and JAK inhibitor-naive adults with moderate-to-severe atopic dermatitis. Patients were randomized to one of three rezpegaldesleukin dosing regimens (24 μg/kg every two weeks, 18 μg/kg every two weeks, or 24 μg/kg every four weeks) or placebo for a 16-week induction period, with the primary endpoint of mean percent change from baseline in Eczema Area and Severity Index (EASI) at Week 16..

REZOLVE-AD 试验在 10 个国家的 107 个研究中心开展，分析了 393 名未接受过生物制剂和 JAK 抑制剂治疗的中重度特应性皮炎成人患者。患者被随机分配至三种 rezpegaldesleukin 给药方案之一（每两周 24 μg/kg、每两周 18 μg/kg 或每四周 24 μg/kg）或安慰剂组，进行为期 16 周的诱导期治疗，主要终点为第 16 周时湿疹面积和严重程度指数（EASI）较基线的平均百分比变化。

'We are pleased to share these important data with the broader medical and scientific community through publication in The Lancet,' said Jonathan Zalevsky, Ph.D., Chief Research and Development Officer of Nektar Therapeutics. 'In 2025, the discovery of T-regs was recognized by the Nobel Prize in Physiology and Medicine.

“我们很高兴通过在《柳叶刀》上发表论文，与更广泛的医学和科学界分享这些重要数据。”Nektar Therapeutics 首席研发官乔纳森·扎莱夫斯基博士表示。“2025年，T调节细胞的发现荣获诺贝尔生理学或医学奖。”

These REZOLVE-AD study results demonstrate, for the first time, that modulation of T-regs represents a novel mechanism for chronic inflammatory disease with no evidence of immunosuppression observed. Unlike current therapeutic strategies available and in late-stage development, which largely focus on inhibiting cytokines to suppress inflammation, rezpegaldesleukin showed no increased risk for viral or bacterial infections in the clinical trials completed to-date in over 1,000 study participants.

这些REZOLVE-AD研究结果首次表明，调节Treg细胞代表了一种慢性炎症性疾病的新机制，且未观察到免疫抑制的证据。与目前可用及处于后期开发阶段、主要侧重于通过抑制细胞因子来抑制炎症的治疗策略不同，在迄今已完成且涉及1000多名受试者的临床试验中，rezpegaldesleukin未显示出增加病毒或细菌感染的风险。

These findings further strengthen the scientific foundation for our ongoing Phase 3 ZENITH AD program in patients with atopic dermatitis.'.

这些发现进一步夯实了我们正在进行的针对特应性皮炎患者的III期ZENITH AD项目的科学基础。

Highlights from the REZOLVE-AD study

REZOLVE-AD 研究亮点

All three dosing regimens met the primary endpoint:

所有三种给药方案均达到了主要终点：

Patients treated with rezpegaldesleukin showed statistically significant, dose-dependent improvement in mean percent reduction in EASI from baseline at Week 16: 61%, 58%, and 53% for the 24 μg/kg q2w, 18 μg/kg q2w, and 24 μg/kg q4w arms, respectively, compared with 31% for placebo (p<0.0001, p<0.0001, and p=0.0002, respectively)..

接受rezpegaldesleukin治疗的患者在第16周时，EASI评分较基线的平均百分比降低呈现出统计学显著且剂量依赖性的改善：24 μg/kg每两周一次（q2w）、18 μg/kg每两周一次（q2w）和24 μg/kg每四周一次（q4w）组的降低幅度分别为61%、58%和53%，而安慰剂组为31%（p值分别为<0.0001、<0.0001和0.0002）。

Key secondary endpoints were met:

达到关键次要终点：

Significant improvements over placebo were observed in EASI-75 (42% vs. 17%), EASI-90 (25% vs. 9%), Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1 response (20% vs. 8%), Itch Numerical Rating Scale (NRS) 4-point reduction (42% vs. 16%), and body surface area (BSA) change from baseline (-54% vs.

在EASI-75（42% vs. 17%）、EASI-90（25% vs. 9%）、研究者对特应性皮炎的总体评估（vIGA-AD）0/1应答率（20% vs. 8%）、瘙痒数值评定量表（NRS）降低4分（42% vs. 16%）以及体表面积（BSA）较基线的变化（-54% vs.

-17%), all favoring rezpegaldesleukin 24 μg/kg q2w..

-17%），均支持每2周一次给予24 μg/kg的rezpegaldesleukin。

Key Patient-Reported Outcome (PRO) Assessments:

关键患者报告结局（PRO）评估：

Rezpegaldesleukin demonstrated statistically significant improvements in patient reported outcomes over placebo at week 16 including ≥ 4-point reduction in Daily Life Quality Index (DLQI) (72% vs. 54%), ≥ 5-point reduction in Atopic Dermatitis Control Tool (ADCT) (67% vs. 35%), ≥ 4-point reduction in Pain Numeric Rating (Pain NRS) (45% vs.

在第16周，Rezpegaldesleukin在患者报告结局方面较安慰剂显示出统计学显著改善，包括日常生活质量指数（DLQI）降低≥4分（72% vs. 54%）、特应性皮炎控制工具（ADCT）评分降低≥5分（67% vs. 35%）、疼痛数字评定量表（Pain NRS）评分降低≥4分（45% vs.

22%) and ≥ 1.25-point reduction in Atopic Dermatitis Sleep Scale (ADSS) item 1 (57% vs. 30%), all favoring rezpegaldesleukin 24 μg/kg q2w..

22%）以及特应性皮炎睡眠量表（ADSS）第1项评分降低≥1.25分（57% vs. 30%），所有结果均有利于rezpegaldesleukin 24 μg/kg每两周一次（q2w）治疗组。

Rapid onset with deepening responses over time:

起效迅速，反应随时间逐渐加深：

Significant EASI improvement was observed as early as Week 2 in the 24 μg/kg dose arms and by Week 4 across all rezpegaldesleukin arms, with responses continuing to deepen through Week 16, indicating potential for further benefit with extended induction treatment.

在24 μg/kg剂量组中，早在第2周就观察到EASI显著改善；在所有rezpegaldesleukin剂量组中，至第4周均观察到EASI显著改善，且疗效在第16周前持续加深，表明延长诱导治疗可能带来进一步获益。

Consistent efficacy across baseline disease severity:

在基线疾病严重程度中保持一致的疗效：

Rezpegaldesleukin demonstrated similar efficacy in patients with moderate (vIGA-AD score 3) and severe (vIGA-AD score 4) disease at baseline.

Rezpegaldesleukin在基线时中度（vIGA-AD评分3分）和重度（vIGA-AD评分4分）患者中显示出相似的疗效。

Meaningful itch relief, including in patients with severe itch:

有意义的止痒效果，包括在严重瘙痒患者中：

Among patients with a baseline Itch NRS score of 7 or greater, Itch NRS response rates were 54% and 49% for the 24 μg/kg q2w and 18 μg/kg q2w arms, respectively, compared with 24% for placebo.

在基线瘙痒数字评分量表（NRS）评分≥7的患者中，24 μg/kg每两周一次组和18 μg/kg每两周一次组的瘙痒NRS应答率分别为54%和49%，而安慰剂组为24%。

Favorable and differentiated safety profile:

良好且差异化的安全性特征：

Safety data for rezpegaldesleukin for the 16-week induction period were consistent with the previously observed and reported safety profile.

Rezpegaldesleukin在16周诱导期内的安全性数据与先前观察和报告的安全性特征一致。

1-3

1-3

Serious adverse events were rare (2%), with no deaths reported during the 16-week induction period and no increased risk of infections, conjunctivitis, or other safety signals associated with currently approved AD therapies.

严重不良事件罕见（2%），在16周的诱导期内未报告死亡病例，且感染、结膜炎或其他与目前获批的特应性皮炎（AD）疗法相关的安全性信号的风险并未增加。

Biomarker data support mechanism of action:

生物标志物数据支持作用机制：

Rezpegaldesleukin dose-dependently reduced key AD biomarkers including TARC/CCL17, periostin, MDC/CCL22, and interleukin-19 in patients with elevated baseline levels, consistent with upstream immunomodulation through T-reg restoration. The results from this trial, corroborated by biomarker evidence of rezpegaldesleukin's mechanistic activity, support a central role of T-reg imbalance in the pathogenesis of atopic dermatitis and IL-2 receptor agonism as an important therapeutic target..

在基线水平升高的患者中，Rezpegaldesleukin 以剂量依赖性方式降低了关键的特应性皮炎（AD）生物标志物，包括 TARC/CCL17、骨膜蛋白、MDC/CCL22 和白细胞介素-19，这与通过恢复调节性 T 细胞（T-reg）实现的上游免疫调节作用一致。本试验的结果得到了 Rezpegaldesleukin 机制活性生物标志物证据的佐证，支持调节性 T 细胞失衡在特应性皮炎发病机制中的核心作用，以及白细胞介素-2 受体激动作为重要治疗靶点的地位。

Phase 3 program underway:

第三阶段计划正在进行中：

Based on T-reg pharmacodynamic findings and overall benefit-risk profile, the 24 μg/kg q2w induction dosing and monthly and quarterly maintenance dosing regimens have been selected for the ZENITH AD Phase 3 program, which is currently enrolling.

基于Treg药效学发现以及整体获益-风险特征，ZENITH AD III期项目已选定24 μg/kg每两周一次的诱导给药方案，以及每月和每季度一次的维持给药方案，该项目目前正在入组中。

The full citation of this article can be accessed at:

本文的完整引用信息可在以下网址获取：

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01143-8/fulltext

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01143-8/fulltext

.

。

Rezpegaldesleukin is currently in Phase 3 development. The registrational program in atopic dermatitis includes three global, randomized, double-blind, placebo-controlled trials: ZENITH AD-1 and ZENITH AD-2 initiated in July 2026, which are currently enrolling biologic and systemic JAK inhibitor treatment-naive patients, and ZENITH AD-3, which will enroll patients with prior systemic biologic and/or JAK inhibitor treatment experience when the study initiates in September 2026.

Rezpegaldesleukin 目前正处于 III 期开发阶段。针对特应性皮炎的注册研究计划包括三项全球性、随机、双盲、安慰剂对照试验：ZENITH AD-1 和 ZENITH AD-2 于 2026 年 7 月启动，目前正在招募未接受过生物制剂和系统性 JAK 抑制剂治疗的患者；ZENITH AD-3 将于 2026 年 9 月启动，届时将招募既往有系统性生物制剂和/或 JAK 抑制剂治疗经验的患者。

In early 2027, we also plan to initiate a single registrational Phase 3 trial in alopecia areata, based upon strong data from our randomized, placebo-controlled Phase 2b REZOLVE-AA study..

2027年初，我们还计划基于随机、安慰剂对照的IIb期REZOLVE-AA研究的有力数据，启动一项针对斑秃的单关键注册性III期临床试验。

About

关于

The Lancet

《柳叶刀》

The Lancet is a world-leading source of clinical, public health, and global health knowledge. Lancet journals have an extensive global reach with more than 33.9 million annual visits and 169.9 million downloaded articles.

《柳叶刀》是临床、公共卫生和全球健康知识的世界领先来源。柳叶刀系列期刊拥有广泛的全球影响力，年访问量超过3,390万次，文章下载量达1.699亿次。

4

4

About Rezpegaldesleukin

关于 Rezpegaldesleukin

Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin is a potential first-in-class disease modifying therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions.

自身免疫性和炎症性疾病会导致免疫系统错误地攻击并损害人体内的健康细胞。机体自身耐受机制的失效使得能够发起这种攻击的致病性T淋巴细胞得以形成。Rezpegaldesleukin是一种潜在的首创疾病修饰疗法，有望纠正多种自身免疫性和炎症性疾病患者体内潜在的免疫系统失衡。

It targets the interleukin-2 receptor complex in the body to stimulate proliferation of powerful inhibitory immune cells known as regulatory T-cells. By activating these cells, rezpegaldesleukin may act to bring the immune system back into balance..

该药物靶向体内的白细胞介素-2受体复合物，以刺激被称为调节性T细胞的强效抑制性免疫细胞的增殖。通过激活这些细胞，rezpegaldesleukin可能有助于使免疫系统恢复平衡。

In February 2025, the U.S. FDA granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

2025年2月，美国食品药品监督管理局（FDA）授予rezpegaldesleukin快速通道资格，用于治疗12岁及以上成人和儿童中重度特应性皮炎患者，这些患者的病情通过外用处方疗法未能得到充分控制，或当此类疗法不适用时。

In July 2025, the FDA granted Fast Track designation for rezpegaldesleukin for the treatment of severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40 kg..

2025年7月，美国食品药品监督管理局（FDA）授予rezpegaldesleukin快速通道资格，用于治疗成人及体重至少40公斤的12岁及以上儿童重度斑秃（AA）。

Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases, including atopic dermatitis, alopecia areata and Type 1 diabetes. It is wholly owned by Nektar Therapeutics.

Rezpegaldesleukin 正在被开发为一种用于多种自身免疫性和炎症性疾病（包括特应性皮炎、斑秃和1型糖尿病）的自注射药物。该药物由 Nektar Therapeutics 全资拥有。

About Atopic Dermatitis

关于特应性皮炎

Atopic Dermatitis is the most common type of eczema, affecting approximately 30 million people in the United States

特应性皮炎是最常见的湿疹类型，在美国影响着约3000万人

5

5

. AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation.

. 特应性皮炎（AD）的特征是皮肤屏障存在缺陷，这使得过敏原和其他刺激物能够进入皮肤，从而引发免疫反应和炎症。

About

关于

Nektar Therapeutics

耐克塔治疗公司

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.

Nektar Therapeutics 是一家处于临床阶段的生物技术公司，专注于开发针对自身免疫性疾病和慢性炎症性疾病潜在免疫功能紊乱的治疗方法。Nektar 的核心候选产品 rezpegaldesleukin（REZPEG，或 NKTR-358）是一种新型、首类调节性 T 细胞刺激剂，目前正在特应性皮炎、斑秃和 1 型糖尿病中进行评估。

Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422..

Nektar 的研发管线还包括处于临床前阶段的双价肿瘤坏死因子受体 II 型（TNFR2）抗体及双特异性项目 NKTR-0165 和 NKTR-0166，以及一种修饰的造血集落刺激因子（CSF）蛋白 NKTR-422。

Nektar is headquartered in San Francisco, California. For further information, visit

Nektar 总部位于加利福尼亚州旧金山。欲了解更多信息，请访问

www.nektar.com

www.nektar.com

and follow us on LinkedIn.

并在 LinkedIn 上关注我们。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release contains forward-looking statements which can be identified by words such as: 'will', 'can,' 'develop,' 'potential,' 'expand,' 'address,' 'may,' 'plan' and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the safety and efficacy profile and therapeutic potential of, and future development plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, and potential patient preferences and market adoption related thereto, and plans and timing of future clinical trials and data releases.

本新闻稿包含前瞻性陈述，可通过“将”、“能够”、“开发”、“潜在”、“扩大”、“解决”、“可能”、“计划”等词语以及对未来期间的类似表述加以识别。前瞻性陈述的示例包括但不限于：关于rezpegaldesleukin、NKTR-0165、NKTR-0166和NKTR-422的安全性和有效性特征、治疗潜力及未来开发计划的陈述；与此相关的潜在患者偏好和市场接受度的陈述；以及未来临床试验和数据发布的计划与时间安排。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions.

前瞻性陈述既非历史事实，亦非对未来表现的保证。相反，它们仅基于我们目前对公司业务未来、未来计划与战略、预期事件与趋势、经济状况以及其他未来条件的信念、预期和假设。

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements.

由于前瞻性陈述涉及未来，它们受到固有的不确定性、风险和情况变化的影响，这些因素难以预测且许多超出我们的控制范围。我们的实际结果可能与前瞻性陈述中指示的结果存在重大差异。

Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued research and development f.

因此，您不应依赖任何前瞻性陈述。可能导致我们的实际结果与前瞻性陈述中指出的结果存在重大差异的重要因素包括（但不限于）：(i) 我们关于 rezpegaldesleukin、NKTR-0165、NKTR-0166 和 NKTR-422 治疗潜力的陈述基于临床前和临床研究结果及观察，并可能随着研发工作的继续而发生变化；(ii) rezpegaldesleukin、NKTR-0165、NKTR-0166 和 NKTR-422 均为研究性药物，其持续研发工作……

Contacts

联系人

For Investors:

致投资者：

Vivian Wu

吴薇薇安

628-895-0661

628-895-0661

[email protected]

[email protected]

Corey Davis, Ph.D.

科里·戴维斯，博士

LifeSci Advisors

生命科学顾问

212-915-2577

212-915-2577

[email protected]

[email protected]

For Media:

媒体专区：

Susan Roberts

苏珊·罗伯茨

LifeSci Communications

生命科学传播

202-779-0929

202-779-0929

[email protected]

[email protected]

Dixit, N. et al. NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.

Dixit, N. 等. NKTR-358：一种新型调节性T细胞刺激剂，可选择性刺激调节性T细胞的扩增及其抑制功能，用于治疗自身免疫性和炎症性疾病。

J Transl Autoimmun.

《转化自免杂志》

2021 May 6;4:100103

2021年5月6日;4:100103

Silverberg, JI. et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

Silverberg, JI. 等。调节性T细胞选择性白细胞介素-2受体激动剂rezpegaldesleukin治疗炎症性皮肤病：两项随机、双盲、安慰剂对照的1b期临床试验。

Nat Commun.

《自然通讯》

2024; 15, 9230

2024；15，9230

Fanton, C. et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.

Fanton, C. 等。NKTR-358 在健康志愿者和系统性红斑狼疮患者中选择性扩增调节性 T 细胞。

J Transl Autoimmun.

《转化自身免疫学杂志》

2022; 5, 100152

2022；5，100152

The Lancet. About The Lancet. Published: 2024. Last assessed: Aug 24, 2026. Available at:

《柳叶刀》。关于《柳叶刀》。发表于：2024年。最近评估日期：2026年8月24日。获取网址：

https://www.thelancet.com/lancet/about

https://www.thelancet.com/lancet/about

.

。

Eczema stats.

湿疹统计数据。

National Eczema Association. (2022,

国家湿疹协会。（2022年，

September 27).

9月27日）。

https://nationaleczema.org/research/eczema-facts/

https://nationaleczema.org/research/eczema-facts/

SOURCE Nektar Therapeutics

来源：Nektar Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示